Literature DB >> 20533297

Activin A and bone metastasis.

Gaetano Leto1.   

Abstract

Activin A, is a multifunctional cytokine of the transforming growth factor-beta superfamily of growth factors. This molecule has been shown to be implicated in the regulation of a broad range of important biological functions including bone remodelling. Therefore, a deregulation in the activin signalling pathway may result in disturbances of normal bone metabolism and, eventually, in the onset of severe pathological conditions associated with an altered bone resorption. These observations support the concept that Act A might also be implicated in the pathogenesis of bone metastasis. This review provides insight into the most recent advances in understanding the role of this growth factor in the pathogenesis of bone metastasis, and discusses the implications related to the biomedical applications of these findings. (c) 2010 Wiley-Liss, Inc.

Mesh:

Substances:

Year:  2010        PMID: 20533297     DOI: 10.1002/jcp.22272

Source DB:  PubMed          Journal:  J Cell Physiol        ISSN: 0021-9541            Impact factor:   6.384


  6 in total

1.  Circulating activin-A is elevated in postmenopausal women with low bone mass: the three-month effect of zoledronic acid treatment.

Authors:  A D Anastasilakis; S A Polyzos; P Makras; A Gkiomisi; M Savvides; A Papatheodorou; E Terpos
Journal:  Osteoporos Int       Date:  2012-11-03       Impact factor: 4.507

Review 2.  Therapeutic targets for bone metastases in breast cancer.

Authors:  Philippe Clézardin
Journal:  Breast Cancer Res       Date:  2011-04-06       Impact factor: 6.466

3.  Metastatic breast cancer cells inhibit osteoblast differentiation through the Runx2/CBFβ-dependent expression of the Wnt antagonist, sclerostin.

Authors:  Daniel Mendoza-Villanueva; Leo Zeef; Paul Shore
Journal:  Breast Cancer Res       Date:  2011-10-27       Impact factor: 6.466

Review 4.  Role of bone-anabolic agents in the treatment of breast cancer bone metastases.

Authors:  Attaya Suvannasankha; John M Chirgwin
Journal:  Breast Cancer Res       Date:  2014       Impact factor: 6.466

5.  Competition between type I activin and BMP receptors for binding to ACVR2A regulates signaling to distinct Smad pathways.

Authors:  Szabina Szófia Szilágyi; Ayelet R Amsalem-Zafran; Keren E Shapira; Marcelo Ehrlich; Yoav I Henis
Journal:  BMC Biol       Date:  2022-02-18       Impact factor: 7.431

Review 6.  Bone Targeted Therapies for Bone Metastasis in Breast Cancer.

Authors:  Wajeeha Razaq
Journal:  J Clin Med       Date:  2013-10-14       Impact factor: 4.241

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.